Voyageur Pharmaceuticals Ltd. (VYYRF)

Overview

Voyageur Pharmaceuticals Ltd. is a company dedicated to the development and commercialization of active pharmaceutical ingredients (API) minerals. Formally known as Voyageur Minerals Ltd., the company underwent a name change in December 2019 to better reflect its focus on pharmaceuticals. It has its headquarters in Calgary, Canada, and is primarily involved in the development of radiographic contrast agents utilized in medical imaging, alongside bromine-based pharmaceutical products. Voyageur Pharmaceuticals holds 100% interest in three barium sulfate (barite) deposits located in British Columbia, Canada, which are of a grade suitable for the pharmaceutical industry. Additionally, the company has interests in a project in Utah, the United States, that is rich in high-grade iodine, lithium, and bromine brine. These strategic mineral assets underpin its product development activities in the pharmaceutical sector.

Products and Services

• Barium and Iodine Radiocontrast Products

  Voyageur Pharmaceuticals is committed to the development of barium and iodine radiocontrast products. These products are crucial components in radiology for enhancing the contrast of structures or fluids within the body in X-ray, computed tomography (CT), and other medical imaging procedures. The company leverages its 100% interest in high-grade barium sulfate deposits, which are instrumental in producing barium-based contrast agents. Additionally, Voyageur’s involvement in a project with high-grade iodine resources supports the development of iodine-based contrast agents, which are essential for a wide range of diagnostic applications, including cardiac imaging, vascular imaging, and CT scans.

• Bromine Based Pharmaceutical Products

  Alongside radiocontrast agents, Voyageur Pharmaceuticals is also focused on the development of bromine-based pharmaceutical products. Bromine compounds have a variety of pharmaceutical applications, including but not limited to the synthesis of sedatives, anticonvulsants, and anesthetics. The company's interest in a brine project in Utah, which is rich in high-grade bromine, positions it to exploit this resource for pharmaceutical applications, contributing to the diversity of its product portfolio.